Search
Search
Mile Brujic, OD, FAAO; Elizabeth Yeu, MD; and William B. Trattler, MD
Show Description +
Mile Brujic, OD, FAAO; Elizabeth Yeu, MD; and William B. Trattler, MD, discuss two cases where the AvaGen Genetic Test (Avellino) provided crucial information for the final treatment decision. The first case saw Dr. Brujic at a crossroads - whether to select a conservative or aggressive treatment plan in a patient with suspected keratoconus. In the second case, Dr. Trattler considers whether to test the 8-year-old son of a mother who had just been diagnosed with unilateral keratoconus.
Posted: 10/01/2021
Mile Brujic, OD, FAAO; Elizabeth Yeu, MD; and William B. Trattler, MD
Mile Brujic, OD, FAAO; Elizabeth Yeu, MD; and William B. Trattler, MD, discuss two cases where the AvaGen Genetic Test (Avellino) provided crucial information for the final treatment decision. The first case saw Dr. Brujic at a crossroads - whether to select a conservative or aggressive treatment plan in a patient with suspected keratoconus. In the second case, Dr. Trattler considers whether to test the 8-year-old son of a mother who had just been diagnosed with unilateral keratoconus.
Posted: 10/01/2021
Identifying Keratoconus Risk with Genetic Testing
AvaGen™, The Genetic Eye Test in Modern Practice
AvaGen Genetic Test Brochure for ECPs
AvaGen Patient Brochure
How CXL and Genetic Testing Fit Into the Keratoconus Game Plan
Genetic Testing Builds Confidence
Common Questions Patients Ask Genetic Counselors and How to Talk to Them About Testing
How are innovations in genetic testing affecting eyecare?
[Genetics and Eyecare Today] How Genetic Data Can Help Guide Decisions
[Genetics and Eyecare Today] The Role of Genetic Testing and Early Keratoconus Diagnosis
About Avellino
Avellino Lab USA, Inc. is a global leader in gene therapy and molecular diagnostics at the forefront of precision medicine for eye care and beyond. With a long-term mission to develop personalized approaches to improve health and disease management through genomics, the company is developing a transformative genetic diagnostics product pipeline, as well as gene therapeutics leveraging CRISPR gene editing, to better manage, and potentially cure, inherited diseases. Avellino is the first privately held, independent company to get an FDA Emergency Use Authorization (EUA).
Visit us online: avellino.com/en/ | avellino.com/en/products/avagen-test/
Follow Avellino
© 2021 Avellino.com All rights reserved.
.00_00_31_24.Still001_1633117824.png?auto=compress,format&w=180)